Fluorescein sodium
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1976
- First approval year
- 1976
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Fluorescein sodium
- Molecular weight
- 376.28
- Structure (SMILES)
- O=C([O-])c1ccccc1-c1c2ccc(=O)cc-2oc2cc([O-])ccc12.[Na+].[Na+]
- fluor amps
- Fluor-amps
- fluorescite
- Fluorescite
- fluorets
- Fluorets
- funduscein 25
- Funduscein-25
- retinofluor
- Retinofluor
- acid yellow 73 sodium salt
- Acid yellow 73 sodium salt
- benzoic acid 2 6 hydroxy 3 oxo 3h xanthen 9 yl disodium salt
- BENZOIC ACID, 2-(6-HYDROXY-3-OXO-3H-XANTHEN-9-YL)-, DISODIUM SALT
- c i 45350
- c i acid yellow 73
- C.i. 45350
- C.i. acid yellow 73
- ci 45350
- Ci 45350
- d c yellow no 8
- D&C YELLOW NO. 8
- fluorescein disodium salt
- Fluorescein disodium salt
- FLUORESCEIN DISODIUM SALT [MI]
- fluorescein disodium salt mi
- fluorescein sodium
- Fluorescein sodium
- FLUORESCEIN SODIUM [EP IMPURITY]
- FLUORESCEIN SODIUM [EP MONOGRAPH]
- FLUORESCEIN SODIUM [JAN]
- FLUORESCEIN SODIUM [MART.]
- FLUORESCEIN SODIUM [ORANGE BOOK]
- FLUORESCEIN SODIUM [USP MONOGRAPH]
- FLUORESCEIN SODIUM [VANDF]
And 40 more, listed on the interactive page.
- CAS registry numbers
- 518-47-8
- ChEMBL ID
- CHEMBL1628233
- InChIKey
- NJDNXYGOVLYJHP-UHFFFAOYSA-L
- RxNorm IDs (RxCUI)
- 57789
- FDA ingredient codes (UNII)
- 93X55PE38X
- 10608
- 3680403
- Applicant
- ALCON LABS INC
- Approval date
- 28 Mar 2006
- Application number
- NDA021980
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Parenteral
- topical
- Condition
- Skin Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000701
- Subject identifier
- D012871
- Condition
- Hyperemia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003822
- Subject identifier
- D006940
- Condition
- Neuroma, Acoustic
- Highest recorded phase
- 2
- Condition identifier
- HP:0009588
- Subject identifier
- D009464
- Condition
- Heart Septal Defects, Atrial
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0007172
- Subject identifier
- D006344
- Condition identifier
- EFO_0000701
- Highest recorded phase
- 2
- Condition identifier
- HP_0009588
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007172
- Highest recorded phase
- 1
- Event
- age-related macular degeneration
- Reports
- 2
- Reporting signal score
- 6.37111
- Event
- anaphylactic reaction
- Reports
- 21
- Reporting signal score
- 39.0265
- Event
- anaphylactic shock
- Reports
- 32
- Reporting signal score
- 101.261
- Event
- blood pressure decreased
- Reports
- 15
- Reporting signal score
- 26.3935
- Event
- cardio-respiratory arrest
- Reports
- 7
- Reporting signal score
- 17.6946
- Event
- chest discomfort
- Reports
- 17
- Reporting signal score
- 24.8342
- Event
- chills
- Reports
- 11
- Reporting signal score
- 10.2521
- Event
- circulatory collapse
- Reports
- 4
- Reporting signal score
- 6.51957
- Event
- cold sweat
- Reports
- 7
- Reporting signal score
- 15.8902
- Event
- consciousness fluctuating
- Reports
- 2
- Reporting signal score
- 7.22526
- Event
- contrast media allergy
- Reports
- 4
- Reporting signal score
- 15.3898
- Event
- dizziness
- Reports
- 20
- Reporting signal score
- 7.44692
- Event
- drug hypersensitivity
- Reports
- 20
- Reporting signal score
- 13.6685
- Event
- dysphonia
- Reports
- 6
- Reporting signal score
- 6.96251
- Event
- dyspnoea
- Reports
- 26
- Reporting signal score
- 11.4439
- Event
- feeling hot
- Reports
- 6
- Reporting signal score
- 7.55562
- Event
- haemangioma congenital
- Reports
- 7
- Reporting signal score
- 35.8888
- Event
- hyperhidrosis
- Reports
- 16
- Reporting signal score
- 19.8513
- Event
- hypersensitivity
- Reports
- 14
- Reporting signal score
- 11.5297
- Event
- laryngeal oedema
- Reports
- 9
- Reporting signal score
- 27.721
- Event
- larynx irritation
- Reports
- 2
- Reporting signal score
- 9.77382
- Event
- loss of consciousness
- Reports
- 15
- Reporting signal score
- 15.9669
- Event
- low birth weight baby
- Reports
- 7
- Reporting signal score
- 18.1757
- Event
- nausea
- Reports
- 52
- Reporting signal score
- 38.3137
- Event
- palpitations
- Reports
- 12
- Reporting signal score
- 13.5443
And 12 more, listed on the interactive page.
- NCT01959230
- NCT01959243
- NCT02519920
- NCT03189134
- NCT04351373
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 75.99
- Calculated partition coefficient (ALogP)
- 3.67
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 27
- Molecular formula
- C20H10Na2O5
- Monoisotopic mass
- 376.03236198
- Natural product
- No
- 0065-0092
- 24208-734
- 51801-003
- 51801-008
- 51801-009
- 54288-179
- 59390-205
- 59390-218
- 82260-734
- 83851-100
- 51662-1533
- 70710-2045
- 70710-2046
- 70771-1969
- 70771-1970
- 81298-8660
- Recorded assays
- 16
- Active assays
- 0
- Contrast Media
- Fluorescent Dyes
Related records
Trials (146)
- "Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Drug B10-FC After Single Administration to Adult Patients".
- 3 Adjuvated Reduced Dose IPV-Al SSI Vaccines and Non-adjuvated Full Dose IPV SSI, as Booster Vaccination to Adolescents
- A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
- A Clinical Endpoint Bioequivalence Study of "Oxymetazoline Hydrochloride Cream"
- A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
- A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
- A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1
- A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers
- A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease
- A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)
- A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Vehicle in Subjects With Blepharitis (P08636)
- A Four Week, Open-Label Study of Azithromycin Ophthalmic Solution, 1% (P08641)
- A Pharmacokinetic (PK) Study of NatrOVA Topical Creme (1%) in Pediatric Subjects 6 to 24 Months of Age
- A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
- A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
- A Study Comparing Oxymetazoline 1% Cream to RHOFADE
- A Study Comparing Tapinarof Cream 1% and Vtama® Cream 1% in the Treatment of Plaque Psoriasis.
- A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD
- A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)
In development for (3)
- Acoustic neuroma Phase 2
- Atrial septal defect 1 Phase 1
- Skin disorder Phase 2